{"entity":{"id":"ima203","kind":"drug","name":"IMA203","aka":["anzutresgene autoleucel","anzu-cel"],"tldr":"IMA203 is an experimental TCR-T cell therapy from Immatics US in phase 3 trials for melanoma, aimed at PRAME.","summary":"IMA203 is a TCR-T cell therapy developed by Immatics US. Its target is PRAME (the sponsor names PRAME). The sponsor states: An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days. ClinicalTrials.gov describes the intervention as: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06743126 (SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma), in melanoma. The largest, NCT06743126, plans to enrol 360 participants with primary completion expected 2028-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of IMA203","url":"https://clinicaltrials.gov/search?intr=IMA203"},{"label":"Sponsor pipeline page","url":"https://www.immatics.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["prame"],"drugs":[],"companies":["immatics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06743126"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"TCR-T cell therapy","mechanism":"An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ima203/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"}],"company":[{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/"}],"trial":[{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/"}]}}